HK1206732A1 - Liquid formulations of salts of 1-[2-(2,4- dimethylphenylsulfanyl)pheny]piperazine 1-[2-(24-)] - Google Patents

Liquid formulations of salts of 1-[2-(2,4- dimethylphenylsulfanyl)pheny]piperazine 1-[2-(24-)]

Info

Publication number
HK1206732A1
HK1206732A1 HK15107256.7A HK15107256A HK1206732A1 HK 1206732 A1 HK1206732 A1 HK 1206732A1 HK 15107256 A HK15107256 A HK 15107256A HK 1206732 A1 HK1206732 A1 HK 1206732A1
Authority
HK
Hong Kong
Prior art keywords
dimethylphenylsulfanyl
pheny
piperazine
salts
liquid formulations
Prior art date
Application number
HK15107256.7A
Other languages
English (en)
Chinese (zh)
Inventor
‧特雷彭達爾
‧洛佩斯德迪戈
Original Assignee
Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42669509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206732(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck As filed Critical Lundbeck As
Publication of HK1206732A1 publication Critical patent/HK1206732A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/08—Lactic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
HK15107256.7A 2009-04-24 2015-07-29 Liquid formulations of salts of 1-[2-(2,4- dimethylphenylsulfanyl)pheny]piperazine 1-[2-(24-)] HK1206732A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900531 2009-04-24

Publications (1)

Publication Number Publication Date
HK1206732A1 true HK1206732A1 (en) 2016-01-15

Family

ID=42669509

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107256.7A HK1206732A1 (en) 2009-04-24 2015-07-29 Liquid formulations of salts of 1-[2-(2,4- dimethylphenylsulfanyl)pheny]piperazine 1-[2-(24-)]

Country Status (35)

Country Link
US (4) US8940746B2 (pt)
EP (1) EP2421534B1 (pt)
JP (1) JP5722879B2 (pt)
KR (1) KR101779214B1 (pt)
CN (2) CN102405048A (pt)
AR (2) AR076400A1 (pt)
AU (1) AU2010238946B2 (pt)
BR (1) BRPI1015338C1 (pt)
CA (1) CA2759456C (pt)
CL (1) CL2011002631A1 (pt)
CO (1) CO6450649A2 (pt)
CR (1) CR20110554A (pt)
DK (1) DK2421534T3 (pt)
DO (2) DOP2011000319A (pt)
EA (1) EA021122B1 (pt)
ES (1) ES2512719T3 (pt)
GE (1) GEP20135938B (pt)
HK (1) HK1206732A1 (pt)
HR (1) HRP20140880T1 (pt)
IL (1) IL215362A0 (pt)
MA (1) MA33298B1 (pt)
MX (1) MX2011011119A (pt)
MY (1) MY155288A (pt)
NZ (1) NZ596431A (pt)
PL (1) PL2421534T3 (pt)
PT (1) PT2421534E (pt)
RS (1) RS53539B1 (pt)
SG (1) SG175124A1 (pt)
SI (1) SI2421534T1 (pt)
SM (1) SMT201400159B (pt)
TN (1) TN2011000504A1 (pt)
TW (1) TWI461224B (pt)
UA (1) UA106985C2 (pt)
WO (1) WO2010121621A1 (pt)
ZA (1) ZA201107731B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2421534T3 (pl) 2009-04-24 2014-12-31 H Lundbeck As Ciekłe preparaty soli 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny
WO2014044721A1 (en) * 2012-09-19 2014-03-27 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
CA2916175A1 (en) 2013-07-01 2015-01-08 Lek Pharmaceuticals D.D. 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form
CN106103418A (zh) 2014-01-31 2016-11-09 埃吉斯药物私人有限公司 沃替西汀盐的制备方法
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104119298B (zh) * 2014-08-13 2016-08-24 北京蓝贝望生物医药科技股份有限公司 氢溴酸沃赛汀或氢溴酸沃替西汀
CN104119299B (zh) * 2014-08-13 2016-08-17 北京蓝贝望生物医药科技股份有限公司 沃赛汀或沃替西汀的氢溴酸盐
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
DK3414216T3 (da) 2016-02-08 2021-01-25 Aaa Chemistry Aps Arylering af alifatiske aminer
KR20190025556A (ko) 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법
CN106518807A (zh) * 2016-09-17 2017-03-22 北京万全德众医药生物技术有限公司 乳酸沃替西汀晶型的制备方法
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN107011289A (zh) * 2017-03-10 2017-08-04 万全万特制药（厦门）有限公司 沃替西汀β晶型的制备方法
GB2564887A (en) * 2017-07-26 2019-01-30 Azad Pharmaceutical Ingredients Ag New route of synthesis to vortioxetine salts
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
AU2004226838B8 (en) 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
WO2007144006A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
PL2044043T5 (pl) * 2006-06-16 2022-05-02 H. Lundbeck A/S Bromowodorek 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny jako związek o połączonym działaniu wychwytu zwrotnego serotoniny i działaniu na 5-ht3 i 5-ht1a do leczenia upośledzenia funckji poznawczych
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
PL2421534T3 (pl) 2009-04-24 2014-12-31 H Lundbeck As Ciekłe preparaty soli 1-[2-(2,4-dimetylofenylosulfanylo)fenylo]piperazyny

Also Published As

Publication number Publication date
ES2512719T3 (es) 2014-10-24
CA2759456A1 (en) 2010-10-28
EP2421534A1 (en) 2012-02-29
US20170224677A1 (en) 2017-08-10
SMT201400159B (it) 2015-01-15
CN102405048A (zh) 2012-04-04
US9475748B2 (en) 2016-10-25
GEP20135938B (en) 2013-10-10
US10034876B2 (en) 2018-07-31
BRPI1015338B1 (pt) 2021-01-05
PT2421534E (pt) 2014-10-29
CA2759456C (en) 2017-10-31
CN104693145A (zh) 2015-06-10
EA201171287A1 (ru) 2012-04-30
MX2011011119A (es) 2011-11-04
DOP2012000211A (es) 2013-03-31
US8940746B2 (en) 2015-01-27
EA021122B1 (ru) 2015-04-30
BRPI1015338C1 (pt) 2021-08-10
NZ596431A (en) 2012-12-21
SG175124A1 (en) 2011-12-29
ZA201107731B (en) 2013-02-27
CO6450649A2 (es) 2012-05-31
AR122051A2 (es) 2022-08-10
DOP2011000319A (es) 2012-02-29
JP2012524735A (ja) 2012-10-18
DK2421534T3 (da) 2014-10-13
TWI461224B (zh) 2014-11-21
HRP20140880T1 (hr) 2014-11-07
PL2421534T3 (pl) 2014-12-31
US10857149B2 (en) 2020-12-08
KR101779214B1 (ko) 2017-09-18
US20120035188A1 (en) 2012-02-09
KR20120022809A (ko) 2012-03-12
MA33298B1 (fr) 2012-05-02
CL2011002631A1 (es) 2012-04-09
IL215362A0 (en) 2011-12-29
BRPI1015338A2 (pt) 2016-05-31
MY155288A (en) 2015-09-30
SI2421534T1 (sl) 2014-11-28
JP5722879B2 (ja) 2015-05-27
AU2010238946A1 (en) 2011-12-08
CR20110554A (es) 2012-02-14
EP2421534B1 (en) 2014-09-03
RS53539B1 (en) 2015-02-27
BRPI1015338B8 (pt) 2021-05-25
WO2010121621A1 (en) 2010-10-28
UA106985C2 (uk) 2014-11-10
US20190167667A1 (en) 2019-06-06
AR076400A1 (es) 2011-06-08
TN2011000504A1 (en) 2013-05-24
TW201041604A (en) 2010-12-01
US20150094316A1 (en) 2015-04-02
AU2010238946B2 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
HK1206732A1 (en) Liquid formulations of salts of 1-[2-(2,4- dimethylphenylsulfanyl)pheny]piperazine 1-[2-(24-)]
IL238068A0 (en) New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine
HK1165955A1 (en) Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine 1-[2-(24-)]
HRP20170918T1 (hr) Soli piperazina kao d3/d2 antagonista
HRP20130819T1 (en) New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
ME02307B (me) Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr
ZA201003909B (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide
AP3583A (en) Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
HK1140949A1 (en) Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-]